Drug Profile


Alternative Names: ALN-PCS; ALN-PCS01; ALN-PCS02

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alnylam Pharmaceuticals
  • Class Antihyperlipidaemics; Small interfering RNA
  • Mechanism of Action PCSK9 protein inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hypercholesterolaemia

Most Recent Events

  • 08 Feb 2017 The Supreme Court of British Columbia grants a pre-trial injunction filed against Acuitas Therapeutics by Arbutus Biopharma for Arbutus's lipid nanoparticle (LNP) technology
  • 05 Nov 2014 Alnylam receives patent allowance for RNA interference technology in USA
  • 08 Feb 2013 Alynylam and The Medicines Company form an agreement for the global development and commercialisation of ALN PCS for hypercholesterolaemia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top